Spectrum Pharmaceuticals Announces Acceptance of New Drug Application Filing for Poziotinib

3 years ago

by David Miller

967 Views

Written by David Miller

HENDERSON, Nev.–(BUSINESS WIRE)–Feb. 11, 2022– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!